Discovery of novel KSP-targeting PROTACs with potent antitumor effects in vitro and in vivo.

Autor: Zhao DG; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China. Electronic address: zhaodenggao@wyu.edu.cn., Liu J; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Su Z; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Zou W; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Zhou Q; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Yin T; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Jiyao T; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Ma YY; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China. Electronic address: j002293@wyu.edu.cn.
Jazyk: angličtina
Zdroj: European journal of medicinal chemistry [Eur J Med Chem] 2025 Jan 15; Vol. 282, pp. 117052. Date of Electronic Publication: 2024 Nov 16.
DOI: 10.1016/j.ejmech.2024.117052
Abstrakt: Kinesin spindle protein (KSP) plays a crucial role during mitosis, making it an attractive target for cancer treatment. Herein, we report the design, synthesis, and evaluation of the first series of KSP degraders by using the utilization of the proteolysis-targeting chimera (PROTAC) technology. Compound 21 was identified as a potent KSP degrader with a DC 50 (concentration causing 50 % of protein degradation) value of 114.8 nM and a D max (maximum degradation) of 90 % in the HCT-116 cells. Compound 21 showed strong antiproliferative activity against HCT-116 cells with an IC 50 values of 10 nM. Mechanistic investigations revealed that 21 causes the cell arrest at the G2/M phase and subsequent cell apoptosis. In addition, 21 demonstrated more significant inhibition of tumor growth in an HCT-116 xenograft model compared to its parent compound 1. Our findings suggest that 21 may become the promising leads for further development.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: